New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
07:09 EDTLGND, SPPILigand Pharmaceuticals deal positive, says Cantor
After Ligand Pharmaceuticals (LGND) announced a license and global supply agreement with Spectrum Pharmaceuticals (SSPI) on Captisol-enabled Melphalan for the treatment of multiple myeloma, Cantor believes the deal is "attractive" for Ligand. The firm, which maintains a Hold rating on Ligand, indicates that it is close to upgrading the stock, but is not doing so because it is still concerned about the company's Promacta generic filer announcement.
News For LGND;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
09:38 EDTLGNDLigand enters license and supply agreement with Vireo Health
Subscribe for More Information
November 20, 2015
07:02 EDTSPPISpectrum submits IND to FDA to initiate Phase 2 breast cancer study
Spectrum Pharmaceuticals announced today the company has submitted an IND application to the U.S. Food and Drug Administration and plans to initiate a Phase 2 breast cancer study in the U.S. as soon as possible. The Phase 2 study is planned to be an open-label study that will enroll approximately 70 patients with HER-2 positive metastatic breast cancer, who have failed at least one or more HER-2 directed therapy. The dose and schedule of oral poziotinib will be based on clinical experience from the studies in Korea, and in addition include the use of prophylactic therapies to help minimize known side-effects of HER2-directed therapies.
November 18, 2015
14:43 EDTLGNDLigand management to meet with Craig-Hallum
Meeting to be held in Minneapolis on November 19 hosted by Craig-Hallum.
10:15 EDTLGNDLigand sees 2017 adjusted EPS over $4.75
Subscribe for More Information
10:12 EDTLGNDLigand reaffirms 2015 adjusted EPS outlook $3.34-$3.37
Subscribe for More Information
05:35 EDTSPPISpectrum divests rights to Zevalin in Japan, other countries
Spectrum Pharmaceuticals announced the divestment of Zevalin rights in Japan and other countries in Asia Pacific, Middle East, Africa and Latin America, to Mundipharma. Spectrum will receive an up-front payment of $15M plus $5M in profits on initial Zevalin supply. Spectrum will continue to own Zevalin rights for U.S., Canada, and Europe.
November 17, 2015
11:25 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 17 at 10 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use